imatinib

/Tag: imatinib

New Data Indicates Imatinib Boosts Long-Term Survival for Some GIST Patients

A significant finding from a newly published study in JAMA Oncology, indicates that nearly one-fourth of GIST patients with advanced disease initially treated with imatinib will survive for ten years or more. The study, [...]

By |2018-10-30T09:19:32+00:00February 27th, 2017|News, Research|

Study Highlights Role of ABL1 in GIST Treated with Imatinib

A recent study published in Oncotarget, discussed the potential role of the kinase, ABL1 as a potential impediment to anti-tumor processes in GIST treated with imatinib mesylate. The Life Raft Group’s Research Team member, [...]

By |2018-10-30T09:23:31+00:00January 19th, 2017|News, Research|

Examining Kidney Toxicities of Sunitinib and Imatinib in Long-Term GIST Therapy

On September 19, 2016 the Life Raft Group was pleased to have Dr. Benjamin D. Humphreys, Chief of the Division of Nephrology at Washington University in St. Louis School of Medicine, share his knowledge [...]

By |2018-10-30T09:34:18+00:00September 19th, 2016|GIST Education, Gleevec, Sutent, Webcast|

Study Finds Adjuvant Systemic Therapy with Imatinib Increasing Over Time

A recent study published in the American Journal of Clinical Oncology found that the use of adjuvant systemic therapy with imatinib for GIST has increased significantly over time, and that patients treated with the [...]

By |2018-10-30T09:55:33+00:00March 15th, 2016|Drug Treatment, News, Survival Strategies|

Generic Imatinib Approved in the US for CML: What does it mean for GIST patients?

Note: The content of this article is current to the time of its posting on February 10, 2016. Please continue to check our site for the latest information on generics. On February 1, 2016, [...]

By |2018-12-17T10:51:32+00:00February 10th, 2016|Drug Treatment, Generics, Gleevec, News, Newsletter|

Adjuvant Imatinib Study Updates Results

A recent study further documented the advantage of three years of adjuvant imatinib versus one year in high-risk GIST patients. The study, which is to be published in the Journal of Clinical Oncology, was authored by [...]

By |2018-10-30T13:56:09+00:00December 16th, 2015|Gleevec, News, Newsletter, Research, Survival Strategies|

Mechanisms of Disease Persistence in Gastrointestinal Stromal Tumors

By Tamas Ordog, LRG Research Team, Martin Zörnig and Yujiro Hayashi Dr. Tamas Ordog Gastrointestinal stromal tumors (GIST) represent a substantial proportion of human bone and soft tissue sarcomas.1 GIST are thought [...]

By |2018-11-01T15:28:03+00:00October 16th, 2015|News, Research|

Study Indicates Use Of Adjuvant Imatinib Therapy For GIST Increasing

A recent study published in the American Journal of Clinical Oncology found that the use of adjuvant systemic therapy with imatinib for GIST has increased significantly over time, and that patients treated with the therapy [...]

By |2018-09-11T09:21:47+00:00April 7th, 2015|Drug Treatment, Gleevec, News, Survival Strategies|

Recent Posts

Upcoming Events

  1. GDOL Los Angeles 2019

    February 16 @ 8:00 AM - 5:00 PM
  2. GIST Laugh

    March 8 @ 7:00 PM - 10:00 PM
  3. GIST DO IT NJ

    May 4 @ 8:00 AM - 11:00 AM